MA27616A1 - Granisetron transdermique - Google Patents

Granisetron transdermique

Info

Publication number
MA27616A1
MA27616A1 MA28419A MA28419A MA27616A1 MA 27616 A1 MA27616 A1 MA 27616A1 MA 28419 A MA28419 A MA 28419A MA 28419 A MA28419 A MA 28419A MA 27616 A1 MA27616 A1 MA 27616A1
Authority
MA
Morocco
Prior art keywords
granisetron
transdermal
transdermal granisetron
skin
flow
Prior art date
Application number
MA28419A
Other languages
English (en)
Inventor
Peter Altenschopfer
Adam Charles Watkinson
Original Assignee
Strakan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9952502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27616(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strakan Ltd filed Critical Strakan Ltd
Publication of MA27616A1 publication Critical patent/MA27616A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des timbres adhésifs destinés à l'administration transdermique de granisetron, qui comprennent un adhésif acrylique contenant des fragments nucléophiles non acides augmentant de manière sensible le flux de granisetron à travers la peau.
MA28419A 2003-02-05 2005-08-01 Granisetron transdermique MA27616A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0302662.2A GB0302662D0 (en) 2003-02-05 2003-02-05 Transdermal granisetron

Publications (1)

Publication Number Publication Date
MA27616A1 true MA27616A1 (fr) 2005-11-01

Family

ID=9952502

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28419A MA27616A1 (fr) 2003-02-05 2005-08-01 Granisetron transdermique

Country Status (32)

Country Link
US (3) US7608282B2 (fr)
EP (1) EP1589956B1 (fr)
JP (2) JP4146486B2 (fr)
KR (1) KR100893158B1 (fr)
CN (3) CN1747724A (fr)
AT (1) ATE368454T1 (fr)
AU (1) AU2004210181B2 (fr)
BR (1) BRPI0407280A (fr)
CA (1) CA2515094C (fr)
CR (1) CR7923A (fr)
CY (1) CY1106811T1 (fr)
DE (1) DE602004007888T2 (fr)
DK (1) DK1589956T3 (fr)
EC (1) ECSP055953A (fr)
ES (1) ES2287695T3 (fr)
GB (1) GB0302662D0 (fr)
GE (1) GEP20084390B (fr)
HR (1) HRP20050695B1 (fr)
IL (1) IL169881A (fr)
IS (1) IS7997A (fr)
MA (1) MA27616A1 (fr)
MX (1) MXPA05008343A (fr)
NO (1) NO331441B1 (fr)
NZ (1) NZ541103A (fr)
PL (1) PL218351B1 (fr)
PT (1) PT1589956E (fr)
RS (1) RS51696B (fr)
RU (1) RU2355387C2 (fr)
SI (1) SI1589956T1 (fr)
UA (1) UA83362C2 (fr)
WO (1) WO2004069141A2 (fr)
ZA (1) ZA200506128B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489865C (fr) 2002-06-25 2012-05-08 Acrux Dds Pty Ltd Commande de debit d'apport transdermique utilisant des compositions pharmaceutiques amorphes
GB0302662D0 (en) * 2003-02-05 2003-03-12 Strakan Ltd Transdermal granisetron
US20070264319A1 (en) * 2004-09-01 2007-11-15 Lebo David B Transdermal Antiemesis Delivery System, Method and Composition Therefor
US20060263421A1 (en) 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
KR20130114229A (ko) 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
CN100464752C (zh) * 2005-11-01 2009-03-04 中国人民解放军第二军医大学 格拉司琼巴布剂及其制法
EP1842541A1 (fr) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Composé et extraits de plantes et leur utilisation
WO2008115599A1 (fr) * 2007-03-21 2008-09-25 Alza Corporation Appareil et procédé d'administration transdermique d'un antagoniste 5-hydroxytrytamine
US20080242696A1 (en) * 2007-03-27 2008-10-02 Chemagis Ltd. Crystalline granisetron base and production process therefor
JP2008297277A (ja) * 2007-06-01 2008-12-11 Taiyo Yakuhin Kogyo Kk 注射剤の安定化法
KR100929560B1 (ko) 2008-01-09 2009-12-03 에코 퍼시픽 엘티디 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
CN101721394B (zh) * 2008-10-29 2013-04-17 大连理工大学 一种格拉司琼和/或其盐酸盐贴剂
TW201021856A (en) 2008-12-01 2010-06-16 Genovate Biotechnology Co Ltd Antiemetic patch
CN101716163B (zh) * 2009-12-24 2013-07-31 沈阳药科大学 一种来曲唑靶向定位缓释透皮贴剂及其制备方法
CN101836949A (zh) * 2010-02-11 2010-09-22 上海现代药物制剂工程研究中心有限公司 含有止吐活性药物的透皮凝胶制剂及制备方法
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
CN102293761B (zh) * 2010-06-22 2014-01-08 浙江省医学科学院 含止吐剂成份的透皮吸收贴剂
CN102462672B (zh) * 2010-11-17 2013-12-04 汪晴 一种雷莫司琼透皮贴剂及其制备方法
CN102178660B (zh) * 2011-04-19 2012-08-08 上海现代药物制剂工程研究中心有限公司 微孔型盐酸格拉司琼透皮贴膜及其制法
WO2013005760A1 (fr) 2011-07-07 2013-01-10 帝國製薬株式会社 Timbre transdermique comprenant un antagoniste des récepteurs de sérotonine
CN106176742A (zh) * 2011-08-01 2016-12-07 江苏康倍得药业股份有限公司 适于透皮给药的含格拉司琼的药物组合物及其制备与应用
WO2014051055A1 (fr) * 2012-09-28 2014-04-03 東レ株式会社 Dérivés de quinuclidine urée et utilisation médicale de ceux-ci
US10232160B2 (en) 2014-04-30 2019-03-19 Sorrento Therapeutics, Inc. Transdermal drug delivery apparatus and methods
CN105520921B (zh) * 2015-01-09 2018-12-25 中国科学院理化技术研究所 一种含有格拉司琼的长效透皮贴剂
CA3047354A1 (fr) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique contenant de l'asenapine et un polysiloxane ou un polyisobutylene
RU2762896C2 (ru) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин
EP3644973B1 (fr) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Système thérapeutique transdermique contenant de l'asénapine et polymère hybride acrylique silicone
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN110958876B (zh) 2018-06-20 2020-12-18 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2020118091A1 (fr) 2018-12-05 2020-06-11 Starton Therapeutics, Inc. Timbre transdermique avec de l'ondansétron inclus dans l'adhésif
KR102537845B1 (ko) 2020-02-19 2023-05-30 신신제약 주식회사 그라니세트론을 함유하는 경피흡수제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269994A (en) * 1963-09-30 1966-08-30 Catalin Corp Of America Solvent-resistant pressure-sensitive adhesive coating and method of producing the same
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
JPH10167956A (ja) * 1996-12-11 1998-06-23 Hisamitsu Pharmaceut Co Inc セロトニン受容体拮抗薬含有経皮投与製剤
CA2276339A1 (fr) * 1997-02-21 1998-08-27 Michael J. Zajaczkowski Systeme d'administration percutanee de medicament adhesif par pression
WO1998053815A1 (fr) 1997-05-30 1998-12-03 Minnesota Mining And Manufacturing Company Dispositif d'administration transdermique de medicament destine a l'administration de tropisetron ou de granisetron
US6312715B1 (en) * 1998-05-01 2001-11-06 3M Innovative Properties Company Adhesive microsphere drug delivery composition
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
ES2261178T3 (es) * 1999-02-09 2006-11-16 Samyang Corporation Una composicion transdermal de un agente anti-vomito y una preparacion de la misma.
JP4378028B2 (ja) * 1999-04-13 2009-12-02 日東電工株式会社 経皮吸収型製剤
EP1044684B1 (fr) * 1999-04-13 2004-07-28 Nitto Denko Corporation Préparation absorbable par voie percutanée
US6465004B1 (en) * 1999-06-05 2002-10-15 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE10015783C2 (de) 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
KR100433614B1 (ko) 2000-06-16 2004-05-31 주식회사 태평양 친수성 또는 염의 형태로 된 약물을 함유하는 경피흡수제제
US20020172712A1 (en) 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
GB0119012D0 (en) * 2001-08-03 2001-09-26 Strakan Group Plc Transdermal delivery of drugs
GB0302662D0 (en) * 2003-02-05 2003-03-12 Strakan Ltd Transdermal granisetron

Also Published As

Publication number Publication date
NZ541103A (en) 2007-01-26
KR100893158B1 (ko) 2009-04-16
CN102416009A (zh) 2012-04-18
RS51696B (sr) 2011-10-31
GEP20084390B (en) 2008-06-10
CN102416009B (zh) 2013-09-11
NO20053663L (no) 2005-11-04
CY1106811T1 (el) 2012-05-23
NO331441B1 (no) 2012-01-02
WO2004069141A3 (fr) 2004-10-07
IL169881A (en) 2011-12-29
US7608282B2 (en) 2009-10-27
ZA200506128B (en) 2006-12-27
NO20053663D0 (no) 2005-07-28
CN102526043A (zh) 2012-07-04
ECSP055953A (es) 2006-01-16
CA2515094C (fr) 2008-12-09
MXPA05008343A (es) 2006-01-31
SI1589956T1 (sl) 2007-10-31
WO2004069141A2 (fr) 2004-08-19
BRPI0407280A (pt) 2006-01-31
GB0302662D0 (en) 2003-03-12
AU2004210181A2 (en) 2004-08-19
PT1589956E (pt) 2007-08-23
US20060177493A1 (en) 2006-08-10
US20120258164A1 (en) 2012-10-11
RS20050600A (sr) 2007-12-31
HRP20050695B1 (hr) 2013-11-08
EP1589956A2 (fr) 2005-11-02
DE602004007888T2 (de) 2008-04-17
IL169881A0 (en) 2007-07-04
CN1747724A (zh) 2006-03-15
DK1589956T3 (da) 2007-10-01
CA2515094A1 (fr) 2004-08-19
AU2004210181A1 (en) 2004-08-19
ATE368454T1 (de) 2007-08-15
UA83362C2 (uk) 2008-07-10
IS7997A (is) 2005-08-24
HK1082199A1 (en) 2006-06-02
HRP20050695A2 (hr) 2006-02-28
KR20050116365A (ko) 2005-12-12
ES2287695T3 (es) 2007-12-16
WO2004069141B1 (fr) 2004-12-23
JP2008195738A (ja) 2008-08-28
JP4146486B2 (ja) 2008-09-10
RU2005127599A (ru) 2006-01-20
AU2004210181B2 (en) 2009-11-19
DE602004007888D1 (en) 2007-09-13
JP2006516601A (ja) 2006-07-06
PL218351B1 (pl) 2014-11-28
PL379027A1 (pl) 2006-06-26
RU2355387C2 (ru) 2009-05-20
CR7923A (es) 2008-10-29
US20100008974A1 (en) 2010-01-14
EP1589956B1 (fr) 2007-08-01

Similar Documents

Publication Publication Date Title
MA27616A1 (fr) Granisetron transdermique
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
ATE461217T1 (de) Glp-1-verbindungen
DK1247097T3 (da) Fremgangsmåde til bestemmelse af effektiviteten af cancerterapi
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
DK1565136T3 (da) Sammensætninger for transdermal oxybutynin-terapi
TR200504892A1 (tr) Belirti göstermeyen tüberküloz tedavisi
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
EP1702683A4 (fr) Catalyseur d'electrode d'oxynitrure metallique
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
EP1572118A4 (fr) Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883
EP1667685A4 (fr) Inhibiteurs du canal potassique a base de quinazoline
WO2004025303A3 (fr) Stress psychologique chez les etres humains
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
ATE443044T1 (de) Tace inhibitoren
DK1604211T3 (da) Identifikation af terapeutiske forbindelser
HRP20090513T1 (hr) S-mirtazapin, namijenjen liječenju napadaja vrućine
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
MXPA05009718A (es) Uso de un fibrato y orlistato para el tratamiento de obesidad.
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
MY137953A (en) New association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent
DK1687301T3 (da) Thiaepothilone til behandling af kræftsygdomme
ATE517108T1 (de) 9-(1',5'-dimethyl-1'-vinyl-4'-hexenyl)-4-hydrox - 7h-furoä3,2-güä1übenzopyran-7-on als antibakterielles mittel
DE60101570D1 (de) Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation